{"id":32364,"date":"2009-04-17T15:57:13","date_gmt":"2009-04-17T15:57:13","guid":{"rendered":"http:\/\/localhost:8888\/wordpress\/raptiva_withdrawn_from_market\/"},"modified":"2024-12-17T16:00:27","modified_gmt":"2024-12-17T21:00:27","slug":"raptiva-withdrawn-from-market","status":"publish","type":"post","link":"https:\/\/www.finchmccranie.com\/blog\/raptiva-withdrawn-from-market\/","title":{"rendered":"Raptiva Withdrawn From Market"},"content":{"rendered":"

Raptiva, a drug manufactured by Roche HoldingAG’s Genentech Inc. and marketed for the treatment of psoriasis has been linked to a rare but often fatal brain disorder. As a result of these findings, Genentech has issued a voluntary recall of the drug.<\/p>\n

Genentech previously disclosed that three cases of the disorder, called progressive multifocal leukoencephalopathy, had turned up in patients taking Raptiva since October of last year. Two of these cases were fatal. A fourth patient died of unknown cause after developing neurologic symptoms. All had been taking the drug for more than three years.<\/p>\n

Last month, Genentech updated the Raptiva label to reflect the increased risk associated with the drug. But the company said it ultimately determined that the risk of the disorder outweighs the benefits of the drug.<\/p>\n

Continue reading<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

Raptiva, a drug manufactured by Roche HoldingAG’s Genentech Inc. and marketed for the treatment of psoriasis has been linked to a rare but often fatal brain disorder. As a result of these findings, Genentech has issued a voluntary recall of the drug. Genentech previously disclosed that three cases of the disorder, called progressive multifocal leukoencephalopathy, […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[40],"tags":[44],"class_list":["post-32364","post","type-post","status-publish","format-standard","hentry","category-personal-injury-wrongful-death","tag-personal-injury"],"yoast_head":"\nRaptiva Withdrawn From Market — Trial Attorney Blog — April 17, 2009<\/title>\n<meta name=\"description\" content=\"Raptiva, a drug manufactured by Roche HoldingAG's Genentech Inc. and marketed for the treatment of psoriasis has been linked to a rare but often fatal — April 17, 2009\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.finchmccranie.com\/blog\/raptiva-withdrawn-from-market\/\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Raptiva Withdrawn From Market — Trial Attorney Blog — April 17, 2009\" \/>\n<meta name=\"twitter:description\" content=\"Raptiva, a drug manufactured by Roche HoldingAG's Genentech Inc. and marketed for the treatment of psoriasis has been linked to a rare but often fatal — April 17, 2009\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Finch McCranie, LLP\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Raptiva Withdrawn From Market — Trial Attorney Blog — April 17, 2009","description":"Raptiva, a drug manufactured by Roche HoldingAG's Genentech Inc. and marketed for the treatment of psoriasis has been linked to a rare but often fatal — April 17, 2009","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.finchmccranie.com\/blog\/raptiva-withdrawn-from-market\/","twitter_card":"summary_large_image","twitter_title":"Raptiva Withdrawn From Market — Trial Attorney Blog — April 17, 2009","twitter_description":"Raptiva, a drug manufactured by Roche HoldingAG's Genentech Inc. and marketed for the treatment of psoriasis has been linked to a rare but often fatal — April 17, 2009","twitter_misc":{"Written by":"Finch McCranie, LLP","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.finchmccranie.com\/blog\/raptiva-withdrawn-from-market\/","url":"https:\/\/www.finchmccranie.com\/blog\/raptiva-withdrawn-from-market\/","name":"Raptiva Withdrawn From Market — Trial Attorney Blog — April 17, 2009","isPartOf":{"@id":"https:\/\/www.finchmccranie.com\/blog\/#website"},"datePublished":"2009-04-17T15:57:13+00:00","dateModified":"2024-12-17T21:00:27+00:00","author":{"@id":"https:\/\/www.finchmccranie.com\/blog\/#\/schema\/person\/4c607d19a3fdb947c462210c077ff4a4"},"description":"Raptiva, a drug manufactured by Roche HoldingAG's Genentech Inc. and marketed for the treatment of psoriasis has been linked to a rare but often fatal — April 17, 2009","breadcrumb":{"@id":"https:\/\/www.finchmccranie.com\/blog\/raptiva-withdrawn-from-market\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.finchmccranie.com\/blog\/raptiva-withdrawn-from-market\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.finchmccranie.com\/blog\/raptiva-withdrawn-from-market\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.finchmccranie.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Raptiva Withdrawn From Market"}]},{"@type":"WebSite","@id":"https:\/\/www.finchmccranie.com\/blog\/#website","url":"https:\/\/www.finchmccranie.com\/blog\/","name":"Trial Attorney Blog","description":"Published by Georgia Trial Lawyers \u2014 Finch McCranie, LLP","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.finchmccranie.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.finchmccranie.com\/blog\/#\/schema\/person\/4c607d19a3fdb947c462210c077ff4a4","name":"Finch McCranie, LLP","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.finchmccranie.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/0ac10eb5fe0f322f70ad7a84f6c73584e7381799013c841fb9f2ecf347e28d71?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0ac10eb5fe0f322f70ad7a84f6c73584e7381799013c841fb9f2ecf347e28d71?s=96&d=mm&r=g","caption":"Finch McCranie, LLP"}}]}},"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/www.finchmccranie.com\/blog\/wp-json\/wp\/v2\/posts\/32364","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.finchmccranie.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.finchmccranie.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.finchmccranie.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.finchmccranie.com\/blog\/wp-json\/wp\/v2\/comments?post=32364"}],"version-history":[{"count":1,"href":"https:\/\/www.finchmccranie.com\/blog\/wp-json\/wp\/v2\/posts\/32364\/revisions"}],"predecessor-version":[{"id":33254,"href":"https:\/\/www.finchmccranie.com\/blog\/wp-json\/wp\/v2\/posts\/32364\/revisions\/33254"}],"wp:attachment":[{"href":"https:\/\/www.finchmccranie.com\/blog\/wp-json\/wp\/v2\/media?parent=32364"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.finchmccranie.com\/blog\/wp-json\/wp\/v2\/categories?post=32364"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.finchmccranie.com\/blog\/wp-json\/wp\/v2\/tags?post=32364"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}